Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer:The Letrozole/Fulvestrant and Avastin (LEA) study

Journal of Clinical Oncology

Volumn 33, Issue 9, 2015, Pages 1045-1052

  Martín, Miguel ^a   Loibl, Sibylle ^l   Von Minckwitz, Gunter ^l   Morales, Serafín ^e   Martinez, Noelia ^b   Guerrero, Angel ^f   Anton, Antonio ^g   Aktas, Bahriye ^l   Schoenegg, Winfried ^l   Muñoz, Montserrat ^h   Garcia Saenz, José Ángel ^c   Gil, Miguel ^j   Ramos, Manuel ^k   Margeli, Mireia ⁱ   Carrasco, Eva ^d   Liedtke, Cornelia ^l   Wachsmann, Grischa ^l   Mehta, Keyur ^l   De La Haba Rodriguez, Juan R ^l  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^d Grupo Español de Investigación en Cáncer de Mama   (Spain)

^e HOSPITAL ARNAU DE VILANOVA   (Spain)

^f Valencian Institute of Oncology   (Spain)

^g HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^h University Hospital Clinic I Provincial   (Spain)

ⁱ HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^j CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^k Residencia Ntra Sra Covadonga 1M Planta Centro   (Spain)

^l Medical Oncology Department Instituto de Investigación Sanitaria Gregorio Marañon Universidad Complutense de Madrid ^*

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIESTROGEN; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BEVACIZUMAB; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; FULVESTRANT; LETROZOLE; METHOTREXATE; TAXANE DERIVATIVE; ESTRADIOL; HORMONE; MONOCLONAL ANTIBODY; NITRILE; TRIAZOLE DERIVATIVE; VASCULOTROPIN A;

ACUTE HEART INFARCTION; ADULT; ADVANCED CANCER; AGED; BLEEDING; BREAST ADENOCARCINOMA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CEREBELLUM INFARCTION; CEREBROVASCULAR ACCIDENT; CHEMOTHERAPY INDUCED ANEMIA; CONFERENCE PAPER; CONTROLLED STUDY; DIARRHEA; DRUG FATALITY; DRUG FEVER; DRUG RESPONSE; DRUG TREATMENT FAILURE; FATIGUE; FEMALE; GERMANY; HEART FAILURE; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; LEUKOPENIA; LIVER DYSFUNCTION; LIVER FAILURE; LUNG EMBOLISM; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SPAIN; STOMATITIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; TIME TO TREATMENT; VERY ELDERLY; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG RESISTANCE; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; FEMALE; GERMANY; HORMONES; HUMANS; MIDDLE AGED; NITRILES; POSTMENOPAUSE; SPAIN; TREATMENT OUTCOME; TRIAZOLES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84927537940     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.57.2388     Document Type: Conference Paper

References (31)

1. Findlay JK: Angiogenesis in reproductive tissues. J Endocrinol 111:357-366, 1986
2. Reynolds LP, Killilea SD, Redmer DA: Angiogenesis in the female reproductive system. FASEB J 6:886-892, 1992
3. Brenner RM, Slayden OD: Cyclic changes in the primate oviduct and endometrium, in Knobil E, Neill JD (eds): The Physiology of Reproduction. New York, NY, Raven Press, 1994, pp 541-569
4. Hyder SM, Stancel GM: Regulation of angiogenic growth factors in the female reproductive tract by estrogens and progestins. Mol Endocrinol 13:806-811, 1999
5. Toi M, Hoshina S, Takayanagi T, et al: Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Jpn J Cancer Res 85:1045-1049, 1994
6. Toi M, Inada K, Hoshina S, et al: Vascular endothelial growth factor and platelet-derived endothelial cell growth factor are frequently coexpressed in highly vascularized human breast cancer. Clin Cancer Res 1:961-996, 1995
7. Brown LF, Berse B, Jackman RW, et al: Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 26:86-91, 1995
8. Yamamoto Y, Toi M, Kondo S, et al: Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. Clin Cancer Res 2:821-826, 1996
9. de Jong JS, van Diest PJ, van der Valk P, et al: Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer: I. An inventory in search of autocrine and paracrine loops. J Pathol 184:44-52, 1998
10. Lee AH, Dublin EA, Bobrow LG, et al: Invasive lobular and invasive ductal carcinoma of the breast show distinct patterns of vascular endothelial growth factor expression and angiogenesis. J Pathol 185:394-401, 1998
11. McLeskey SW, Tobias CA, Vezza PR, et al: Tumor growth of FGF or VEGF transfected MCF-7breast carcinoma cells correlates with density of specific microvessels independent of the transfected angiogenic factor. Am J Pathol 153:1993-2006, 1998
12. Ross RK, Paganini-Hill A, Wan PC, et al: Effect of hormone replacement therapy on breast cancer risk: Estrogen versus estrogen plus progestin. J Natl Cancer Inst 92:328-332, 2000
13. Rossouw JE, Anderson GL, Prentice RL, et al: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333, 2002
14. Chlebowski RT, Hendrix SL, Langer RD, et al: Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: The Women's Health Initiative Randomized Trial. JAMA 289:3243-3253, 2003
15. Hyder SM, Stancel GM, Chiappetta C, et al: Uterine expression of vascular endothelial growth factor is increased by estradiol and tamoxifen. Cancer Res 56:3954-3960, 1996
16. Nakamura J, Savinov A, Lu Q, et al: Estrogen regulates vascular endothelial growth/permeability factor expression in 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors. Endocrinology 137:5589-5596, 1996
17. Nakamura J, Lu Q, Aberdeen G, et al: The effect of estrogen on aromatase and vascular endothelial growth factor messenger ribonucleic acid in the normal nonhuman primate mammary gland. J Clin Endocrinol Metab 84:1432-1437, 1999
18. Liang Y, Hyder SM: Proliferation of endothelial and tumor epithelial cells by progestin-induced vascular endothelial growth factor from human breast cancer cells: Paracrine and autocrine effects. Endocrinology 146:3632-3641, 2005
19. Schoeffner DJ, Matheny SL, Akahane T, et al: VEGF contributes to mammary tumor growth in transgenic mice through paracrine and autocrine mechanisms. Lab Invest 85:608-623, 2005
20. Foekens JA, Peters HA, Grebenchtchikov N, et al: High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res 61:5407-5414, 2001
21. Manders P, Beex LV, Tjan-Heijnen VC, et al: Vascular endothelial growth factor is associated with the efficacy of endocrine therapy in patients with advanced breast carcinoma. Cancer 98:2125-2132, 2003
22. Borgström P, Gold DP, Hillan KJ, et al: Importance of VEGF for breast cancer angiogenesis in vivo: Implications from intravital microscopy of combinationtreatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res 19:4203-4214, 1999
23. Traina TA, Rugo HS, Caravelli JF, et al: Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer. J Clin Oncol 28:628-633, 2010
24. Forero-Torres A, Saleh MN, Galleshaw JA, et al: Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast cancer. Clin Breast Cancer 10:275-280, 2010
25. National Cancer Institute: Common Terminology Criteria for Adverse Events, version 3.0.Bethesda, MD, Cancer Therapy Evaluation Program,2006. http://ctep.cancer.gov/protocolDevelopment/ electronic-applications/docs/ctcaev3.pdf
26. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
27. Mouridsen HT: Letrozole in advanced breast cancer: The PO25 trial. Breast Cancer Res Treat 105:19-29, 2007 (suppl 1)
28. Mouridsen H, Gershanovich M, Sun Y, et al: Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the international letrozole breast cancer group. J Clin Oncol 21:2101-2109, 2003
29. Miles DW, Diéras V, Cortés J, et al: First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: Pooled and subgroup analyses of data from 2447 patients. Ann Oncol 24:2773-2780, 2013
30. Kaufman B, Mackey JR, Clemens MR, et al: Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: Results from the randomized phase III TAnDEM study. J Clin Oncol 27:5529-5537, 2009
31. Johnston S, Pippen J Jr, Pivot X, et al: Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 27:5538-5546, 2009